标题
PCSK9 inhibitors for treating hypercholesterolemia
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 3, Pages 353-363
出版商
Informa UK Limited
发表日期
2020-01-02
DOI
10.1080/14656566.2019.1702970
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL
- (2019) Raul Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
- (2019) Željko Reiner Current Atherosclerosis Reports
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
- (2019) J. Wouter Jukema et al. CIRCULATION
- PCSK9 inhibitors in clinical practice: Expectations and reality
- (2018) Željko Reiner ATHEROSCLEROSIS
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
- (2018) Angelos D. Karagiannis et al. Current Atherosclerosis Reports
- Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
- (2018) Henry N. Ginsberg et al. Diabetes Therapy
- Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
- (2018) Henry N. Ginsberg et al. Diabetes Therapy
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
- (2018) Michel Farnier et al. ATHEROSCLEROSIS
- Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies
- (2018) Erik Stroes et al. CLINICAL CARDIOLOGY
- Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
- (2018) Konstantinos C. Koskinas et al. CLINICAL CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Haidong Wang et al. LANCET
- Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
- (2017) Jiao Li et al. Molecular Medicine Reports
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibodies in Patients Treated with Alirocumab
- (2017) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
- (2017) Michael J. Koren et al. JAMA Cardiology
- A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
- (2016) Arihiro Kiyosue et al. AMERICAN JOURNAL OF CARDIOLOGY
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- (2016) Eli M. Roth et al. ATHEROSCLEROSIS
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
- (2016) Nicola Ferri et al. ATHEROSCLEROSIS
- Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
- (2016) Ioanna Gouni-Berthold et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
- (2016) Henry N. Ginsberg et al. CARDIOVASCULAR DRUGS AND THERAPY
- Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
- (2016) Vera Bittner CIRCULATION
- Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
- (2016) Patrick M. Moriarty et al. EUROPEAN HEART JOURNAL
- Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
- (2016) Roberto Ferrari et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
- (2016) Erik Stroes et al. Journal of the American Heart Association
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
- (2016) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- PCSK9 inhibitors – past, present and future
- (2015) Željko Reiner Expert Opinion on Drug Metabolism & Toxicology
- Discontinued cardiovascular drugs in 2013 and 2014
- (2015) Hong-ping Zhao et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
- (2015) Robert P. Giugliano et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Management of patients with familial hypercholesterolaemia
- (2015) Željko Reiner Nature Reviews Cardiology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 inhibition to reduce cardiovascular disease risk
- (2015) Hagai Tavori et al. Current Opinion in Endocrinology Diabetes and Obesity
- AMG-145
- (2014) E.A. Stein et al. DRUGS OF THE FUTURE
- Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force
- (2014) Bulent Gorenek et al. EUROPACE
- Update on the efficacy of statin treatment in acute coronary syndromes
- (2014) Gian Marco Rosa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Takotsubo cardiomyopathy and torsade de pointes in myasthenic crisis: be aware of QT prolongation
- (2013) Alberto Valbusa et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Statins in the primary prevention of cardiovascular disease
- (2013) Željko Reiner Nature Reviews Cardiology
- Síndrome de tako-tsubo e insuficiencia cardiaca: seguimiento a largo plazo
- (2012) Iván J. Núñez-Gil et al. REVISTA ESPANOLA DE CARDIOLOGIA
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Acute Heart Failure Syndromes in Patients With Coronary Artery Disease
- (2009) James D. Flaherty et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dyslipidemia and cardiovascular risk: the importance of early prevention
- (2009) M. Miller QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started